Bajaj Healthcare's stock has surged, fuelled by regulatory approvals and expansion into high-growth markets. But with a history of financial struggles, the real test is whether this rally has staying power.

Bajaj Healthcare Ltd. is trading below all available SMAs

Bajaj Healthcare Ltd.

19 Mar 2025

492.60

2.94%

Bajaj Healthcare shares gain 10%, hits all time high in trade; here's why

Business Standard

Cenobamate is an advanced anti-seizure medication used for the treatment of partial-onset seizures in adults

Number of FII/FPI investors increased from 8 to 14 in Mar 2025 qtr.

Bajaj Healthcare Ltd.

19 Mar 2025

492.60

2.94%

Company Update

Bajaj Healthcare Ltd - 539872 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

The Company has received recommendation from SEC (Neurology & Psychiatry) of CDSCO to conduct Phase III clinical trials for Cenobamate Tablets

pdf

Bajaj Healthcare Ltd.

04 Mar 2025

492.60

2.94%

Company Update

Bajaj Healthcare Ltd - 539872 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation of schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

pdf

Bajaj Healthcare Ltd.

25 Feb 2025

492.60

2.94%

SAST

Bajaj Healthcare Ltd - 539872 - Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(ii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sajankumar Rameshwarlal Bajaj

pdf

Is Bajaj Healthcare Ltd. worth buying?

127 Votes:

Buy 77.95%

Sell 8.66%

Hold 13.39%